AbbVie Inc. SG&A Expense 2011-2026 | ABBV
Beta
What is sg&a expense?
Selling, general, and administrative expenses include all non-production costs such as marketing, corporate overhead, and management salaries.
What is AbbVie Inc.'s current sg&a expense?
AbbVie Inc. (ABBV) annual sg&a expense for 2025 was $14.01B, a 5.03% decline from 2024. AbbVie Inc. sg&a expense for the quarter ending March 31, 2026 was $3.58B.
What was AbbVie Inc.'s sg&a expense in 2024?
AbbVie Inc. annual sg&a expense for 2024 was $14.75B, a 14.61% increase from 2023.
What was AbbVie Inc.'s sg&a expense in 2023?
AbbVie Inc. annual sg&a expense for 2023 was $12.87B, a 15.65% decline from 2022.
What is AbbVie Inc.'s 5-year sg&a expense CAGR?
AbbVie Inc. sg&a expense grew at a compound annual growth rate (CAGR) of 4.39% from FY2020 to FY2025, going from $11.30B to $14.01B over 5 years.
SG&A Expense History
Year-over-year comparison from 10-K annual reports
Key Statistics
Trend Direction
Stable
CAGR+4.4%
FY2020
$11.30B
→
FY2025
$14.01B
111213141516171819202122232425
5 years selected
SG&A Expense History
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $14.01B | -5.0% | 10-K |
| FY2024 | $14.75B | +14.6% | 10-K |
| FY2023 | $12.87B | -15.6% | 10-K |
| FY2022 | $15.26B | +23.6% | 10-K |
| FY2021 | $12.35B | +9.3% | 10-K |
| FY2020 | $11.30B | +62.8% | 10-K |
| FY2019 | $6.94B | -6.2% | 10-K |
| FY2018 | $7.40B | +17.5% | 10-K |
| FY2017 | $6.29B | +7.0% | 10-K |
| FY2016 | $5.88B | -7.9% | 10-K |
| FY2015 | $6.39B | -17.3% | 10-K |
| FY2014 | $7.72B | +44.3% | 10-K |
| FY2013 | $5.35B | +7.3% | 10-K |
| FY2012 | $4.99B | -15.4% | 10-K |
| FY2011 | $5.89B | - | 10-K |
Company: AbbVie Inc.Ticker: ABBVSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →